AbbVie sees hope in hepatitis C, cancer drugs in development
This article was originally published in Scrip
AbbVie financial chief Bill Chase told investors that the company is in good position to capture a piece of the market for hepatitis C treatments and touted the company’s experimental cancer therapies in development.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.